Clinical

Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.

Medical experts discuss potential solutions to mitigate preventable challenges in cardiovascular disease treatment, such as reforming the fee-for-service system and implementing value-based care models.

Panelists discuss financial obstacles, out-of-pocket costs, prior authorizations, and the inpatient/outpatient care paradigm.

The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.

The panel discusses remaining gaps in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment and shares perspectives on optimal practices and care settings for managing this disease.

Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.

Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.

An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.

The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.

The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.

Pamela J. McShane, MD, explores the clinical manifestations of bronchiectasis, including productive chronic cough, hemoptysis, and recurrent respiratory infections, while emphasizing the importance of CT scans in revealing improper airway narrowing and addressing the misdiagnosis of COPD and asthma.

A medical professional discusses the process of diagnosis of type 1 diabetes, including challenges that emerge during screening and considerations for improving the pathway.

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS).

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).

COVID-19 vaccination was associated with reduced risks of acute and post–acute COVID-19 heart failure, venous thromboembolism, and arterial thrombosis/thromboembolism.